Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Endocrinology | Neurology | Podiatry | Orthopedics/Orthopedic Surgery
Disease Category: Diabetic Neuropathy
Location: United States, IL
The purpose of this study is to evaluate the safety and effectiveness of pregabalin (Lyrica) compared to placebo (inactive substance) in subjects with diabetic peripheral neuropathy who have not experienced adequate pain relief from other treatments.
If you qualify to participate in the study, you will be randomly assigned by chance (like the flip of a coin) to receive either pregabalin or placebo (inactive substance). You will have an equal (50/50) chance of being assigned to either pregabalin or placebo in one part of the study.
The first 6-week period of the study is single-blind, which means that you will not know to which study drug you are assigned, but the doctor will know to which study drug you are assigned. If, after the first 6 weeks of the study, you continue to qualify to participate in the study, you will begin the 13-week treatment period. This 13-week period of the study is double-blind, which means neither you nor the study doctor will know to which study drug you are assigned. However, the study doctor can get this information in case of an emergency.
Study inclusion / exclusion criteria:
- Men or women who are 18 years of age or older.
- You must be currently diagnosed with Type 1 or Type 2 diabetes.
- You must be currently taking pain medication for diabetic peripheral neuropathy.
Chicago Research Center, Inc
3401 N Central Avenue
Chicago, IL 60634
Research Center Information: Chicago Research Center, Inc
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these